Japan's Takeda has secured its first regulatory approval – in Indonesia – for its dengue fever vaccine TAK-003, which has been tipped as a potential blockbuster product.

Takeda has unexpectedly withdrawn its marketing application with the FDA for dengue fever vaccine TAK-003 and said it will reconsider whether it will attempt to bring it to market in the US.

HYDERABAD: Japanese pharma giant Takeda has entered into a strategic partnership with Hyderabad-based biopharma player Biological E Limited (BE), to manufacture up to 50 million doses of Takeda ...

HYDERABAD: Takeda and Biological E Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, on Tuesday, announced a strategic partnership to accelerate access to QDENGA (Dengue ...

In a large trial, a dengue immunization developed by Takeda Vaccines reduced the number of dengue by more than 80 percent relative to a control group, and cut the number of hospitalizations due to the ...

India experiences the world’s absolute burden of at least 11 NTDs, including hookworm, dengue, lymphatic filariasis, leprosy, ...

Brazil's drug regulatory agency has approved Japan-based Takeda's four-strain vaccine against dengue virus for use in people ages 4 to 60 years old, the company announced yesterday. Takeda's vaccine ...

Why is there still no dengue vaccine in the country?” This was the question posed by Union of Local Authorities of the Philippines president and Quirino governor Dax Cua to the Department of Health, a ...

Ecuador's Health Ministry confirmed Thursday that the South American country was going through a dengue epidemic.

The development of dengue vaccine has been a focus of utmost importance ... attenuated vaccine based on DENV2-PDK-53 CDC/Inviragen/Takeda Phase II Live-attenuated vaccine based on DEN4Δ30 ...

Brazilian President Luiz Inácio Lula da Silva and World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus Monday discussed producing a vaccine against dengue during their ...